NYSE Arca · PLX
Protalix BioTherapeutics, Inc. (DE)
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PLX: Nov 12, 2026
Protalix BioTherapeutics, Inc. (DE) Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.02. The reported EPS for the same quarter last year was $0.03.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.02 | $0.01 | $-0.05 | 2 |
| Dec 2026 | $-0.01 | $0.01 | $-0.04 | 2 |
| Mar 2027 | $0.01 | $0.01 | $0.01 | 1 |
| Jun 2027 | $0.01 | $0.01 | $0.01 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · RTTNews · BNK Invest · Fintel- The Motley Fool · Aug 19, 10:28 AM EDTProtalix (PLX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Mar 18, 9:19 PM EDTProtalix Stock Down As FY25 Results Show Net Loss, Fabry Milestones Boosts Outlook(RTTNews) – Protalix BioTherapeutics, Inc. (PLX) has reported fiscal year 2025 results, highlighting steady product revenues but a swing to net loss compared with the prior year.
- BNK Invest · Mar 18, 11:59 AM EDTWednesday Sector Laggards: Precious Metals, Biotechnology StocksIn trading on Wednesday, precious metals shares were relative laggards, down on the day by about 5.6%. Helping drag down the group were shares of I-80 Gold, off about 13.6% and shares of Novagold Resources down about 9.8% on the day. Also lagging the market Wednesday are biote
- RTTNews · Mar 13, 10:16 AM EDTEuropean Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication(RTTNews) – The European Commission delivered notable regulatory decisions this week – expanding the indication for Johnson & Johnson's prostate cancer therapy, approving a new dosing regimen for Protalix BioTherapeutics' enzyme replacement therapy Elfabrio, and granting a second
- Fintel · Feb 4, 1:08 PM ESTProtalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $11.22 / share. This is a decrease of 12.00% from the prior estimate of $12.75 dated January 11, 2026. The price target is an average of many targets provided by an
- RTTNews · Dec 17, 7:24 AM ESTProtalix, Secarna Partner To Develop ASO Treatments For Rare Renal Conditions(RTTNews) – Wednesday, Protalix BioTherapeutics, Inc. (PLX) announced a collaboration and option agreement with Secarna Pharmaceuticals GmbH & Co. KG, a Germany-based biopharmaceutical company, to discover novel antisense oligonucleotide or ASO therapies against multiple targets
- Fintel · Dec 5, 10:03 PM ESTProtalix BioTherapeutics (PLX) Price Target Decreased by 10.71% to 12.75The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $12.75 / share. This is a decrease of 10.71% from the prior estimate of $14.28 dated November 14, 2025. The price target is an average of many targets provided by a
- Fintel · Nov 21, 7:02 AM ESTHC Wainwright & Co. Maintains Protalix BioTherapeutics (PLX) Buy RecommendationFintel reports that on November 21, 2025, HC Wainwright & Co. maintained coverage of Protalix BioTherapeutics (NYSEAM:PLX) with a Buy recommendation. Analyst Price Forecast Suggests 720.69% Upside
- The Motley Fool · Aug 14, 7:14 AM EDTProtalix Revenue Jumps 16 Percent in Q2Revenues from product sales grew 16% year-over-year in Q2 2025, modestly exceeding analyst expectations on a GAAP basis.
- RTTNews · Jul 21, 7:32 AM EDTProtalix BioTherapeutics Names Gilad Mamlok CFO(RTTNews) – Protalix BioTherapeutics, Inc. (PLX), Monday announced the appointment of Gilad Mamlok as new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin.
- RTTNews · May 20, 3:00 PM EDTProtalix BioTherapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 4:30 PM ET(RTTNews) – Protalix BioTherapeutics Inc. (PLX) will present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, Nasdaq World Headquarters, New York.
- Quiver Quantitative · May 9, 7:30 AM EDT$PLX Earnings Results: $PLX Reports Quarterly Earnings$PLX ($PLX) posted quarterly earnings results on Friday, May 9th. The company reported earnings of -$0.05 per share, missing estimates of $0.03 by $0.08. The company also reported revenue of $10,110,000, missing estimates of $21,816,000 by $-11,706,000.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Protalix BioTherapeutics, Inc. (DE) from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.